Abiopharma

Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

(70% Positive) MiMedx Group Inc (MDXG) Reports Q1 2026 Financial Results

(70% Positive) Butterfly Network Inc. (BFLY) Announces Business Combination

(85% Positive) Akebia Therapeutics Inc (AKBA) Announces Enrollment Update for expected Due to Geopolitical Situation, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(100% Positive) BioLife Solutions Inc (BLFS) Reports Q1 2026 Financial Results

Butterfly Network, Inc. - Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2025 Revenue Growth of at least 17% Year over Year

(70% Positive) Establishment Labs Holdings Inc (ESTA) Reports Q1 2026 Financial Results

(90% Positive) Catalyst Pharmaceuticals Inc. (CPRX) Announces Business Combination

(99% Positive) Apyx Medical Inc (APYX) Reports Q1 2026 Financial Results

Vir Biotechnology - Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

(30% Negative) Cabaletta Bio Inc (CABA) Announces Delay in expected Trials for 1H26 to confirm GMP readiness Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

Nuvation Bio Inc. - Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

(10% Negative) Novavax Inc (NVAX) Announces Delay in delivery Trials for its COVID-19 vaccine Due to Pandemic-Related Challenges, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment